Kwon et al., 2019 - Google Patents
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study …Kwon et al., 2019
- Document ID
- 2509635540800786793
- Author
- Kwon J
- Yoo S
- Nam S
- Kim H
- Kim C
- You C
- Choi S
- Cho S
- Han J
- Song D
- Chang U
- Yang J
- Lee S
- Lee H
- Han N
- Kim S
- Song M
- Sung P
- Jang J
- Bae S
- Choi J
- Yoon S
- Publication year
- Publication venue
- Journal of Medical Virology
External Links
Snippet
Background A real‐life study is essential outside clinical trials. The aim is to evaluate the clinical outcomes of direct acting agents (DAA) for patients with chronic hepatitis C (CHC) in real practice. Methods We analyzed 590 consecutively enrolled patients with CHC‐1b who …
- 241000711549 Hepacivirus C 0 title description 28
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yoshimi et al. | Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy | |
Agarwal et al. | Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment | |
Chan et al. | Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B | |
Asselah et al. | Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis | |
Miyaki et al. | Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients | |
Wong et al. | Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease | |
El‐Khayat et al. | Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4 | |
Mücke et al. | No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort | |
Papatheodoridis et al. | Hepatocellular carcinoma risk in HB eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet. Greece cohort | |
Kosaka et al. | Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 | |
Moucari et al. | Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C | |
Goel et al. | Daclatasvir and reduced‐dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate< 30 mL/min | |
Itakura et al. | Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy | |
Mizokami et al. | Resistance analyses of Japanese hepatitis C‐infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies | |
Ueno et al. | Prevention of hepatocellular carcinoma complicating chronic hepatitis C | |
Ahn et al. | A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus | |
Uchida et al. | Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism | |
Vassiliadis et al. | Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg‐chronic hepatitis B patients: A 4‐year study | |
Everson et al. | Daclatasvir+ asunaprevir+ beclabuvir±ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients | |
Kwon et al. | Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study in Korea | |
Morio et al. | Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients | |
Fourati et al. | Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS 5A inhibitor | |
Kao et al. | Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 study | |
Kao et al. | Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis | |
Mushtaq et al. | Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan |